Octreotide therapy in dumping syndrome: Analysis of long-term results.
BACKGROUND
Octreotide therapy is effective in controlling severe dumping symptoms during short-term follow-up but little is known about long-term results.


OBJECTIVE
To report on the long-term results of patients with severe dumping syndrome treated at the Leiden University Medical Center with subcutaneous or depot intramuscular (long-acting release) octreotide.


METHODS
Follow-up of 34 patients with severe dumping syndrome refractory to other therapeutic measures treated between 1987 and 2005 with octreotide subcutaneous/long-acting release. At regular intervals symptoms, quality of life, weight, faecal fat excretion and gallstone formation were evaluated.


RESULTS
All patients had excellent initial relief of symptoms during octreotide subcutaneous therapy. However, during follow-up 16 patients stopped therapy because of side effects (n = 9) or loss of efficacy (n = 7). Four patients died. Fourteen patients (41%) remain using octreotide (follow-up 93 +/- 15 months), seven are on octreotide subcutaneous and seven on octreotide long-acting release. Patients with severe dumping (both early and late) do better on subcutaneous than long-acting release despite the inconvenience of frequent injections. Dumping symptoms are reduced by 50% even in long-term users. Body weight continues to increase during therapy despite more pronounced steatorrhoea.


CONCLUSIONS
The long-term the efficacy of octreotide is much less favourable compared with short-term treatment.
Didden
P
P
Department of Gastroenterology-Hepatology, Leiden University Medical Center, Leiden, the Netherlands.
Penning
C
C
Masclee
A A M
AA
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D003692:Delayed-Action Preparations; D004377:Dumping Syndrome / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D005765:Gastrointestinal Agents / Q000008:administration & dosage*; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage*; D016896:Treatment Outcome
D001786:Blood Glucose; D003692:Delayed-Action Preparations; D005765:Gastrointestinal Agents; D015282:Octreotide